摘要:
The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.
摘要:
The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.
摘要:
The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.
摘要:
A backlight unit including a light guide plate, a light source comprising a plurality of color light emitting diodes, and an optical member comprising a diffusion sheet on the light guide plate, wherein the diffusion sheet comprises a plurality of color patterns that are located outside of an area that overlaps with an active area, where each of the color light emitting diodes is positioned in an area adjacent to the color pattern of a different color, and a liquid crystal display including the same are disclosed.
摘要:
The present disclosure relates to a back light unit having an LED array structure for reducing light leakage problem at edge portion. A liquid crystal display device comprises a liquid crystal display panel; an optical sheet disposed under the liquid crystal display panel; and an LED array having red LED, green LED and blue LED are sequentially arrayed under the optical sheet, wherein one portion of an outermost LED of the LED array is included within an area covered by the liquid crystal display panel, and other portion of the outermost LED of the LED array is excluded from the area covered by the liquid crystal display panel.